

Effect of Genetic Polymorphism on the Clinical Response to Valproate Therapy in Epileptic Children

Thesis

**Submitted for the Partial Fulfilment of the Philosophy Doctor (PhD) Degree in
Pharmaceutical Sciences (Clinical Pharmacy)**

By

Pharmacist / Engi Abd-el Hady Abd-el Hady Ibrahim

Master Degree in Clinical Pharmacy

Ain Shams University

Under the Supervision of

Prof. Dr. Osama Ahmed Badary

Professor of Clinical Pharmacy

Faculty of Pharmacy

Ain Shams University

Chairman of National

Organization for Drug Control &

Research

Prof. Dr. Manal Hamed El

Hamamsy

Professor of Clinical Pharmacy

Vice Dean for Community Services and

Environmental Development Affairs

Faculty of Pharmacy

Ain Shams University

Prof. Dr. Mohamad Abd-el Adl

Elsawy

Professor of Pediatrics and

Genetics

Faculty of Medicine

Prof. Dr. Sahar Mohamed Ahmed

Hassanein

Professor of Pediatrics

Head of Neuropediatric Unit

Faculty of Medicine

Ain Shams University

Prof. Dr. Manal Zaghlol Mahran

Professor of Clinical Pathology

Faculty of Medicine

Ain Shams University

2014

Acknowledgements

First and foremost, I am deeply thankful to Allah by the grace of whom, this work was achievable.

I thank my supervisors whose assistance and dedicated involvement in every step throughout this work made it accomplished. I would like to thank them very much for their support and understanding over these past five years.

I am deeply indebted to **Prof. Dr. Osama Ahmed Badary**, Professor of Clinical Pharmacy, Faculty of pharmacy, Ain Shams University, for his earnest support, valuable foresight, and careful guidance throughout the preparation of this study.

I am very grateful to **Prof. Dr. Mohamad Abd-el Adl El-Sawy**, Professor of Pediatrics, Faculty of Medicine, Ain Shams University and former Head of Genetics center, for helping me in selecting the topic, his encouragement, and continuous support.

I would like also to express my sincerest gratitude and appreciation to **Prof. Dr. Manal Hamed El Hamamsy**, professor of Clinical Pharmacy, whose contribution in stimulating suggestions and encouragement helped me to coordinate my work especially in writing this dissertation.

I am very thankful to **Prof. Dr. Sahar Mohamed Ahmed Hassanein**, Professor of Pediatrics and Head of Neuropediatric Unit, Faculty of Medicine, Ain Shams University, for her generous assistance, beneficial discussions and valuable guidance with the patients' facility aspects.

A special gratitude I give to **Prof. Dr. Manal Zaghlol Mahran**, Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her keen supervision and unfailing advice.

Furthermore I would also like to acknowledge with much appreciation the crucial role of the staff of Clinical pathology and immunology laboratory, for their technical and instrumental support to perform the genetic analysis. My deep gratitude goes especially to **Dr. Nesrine Ali Mohamed**, lecturer of Clinical Pathology & Immunology, Faculty of Medicine, Ain Shams University.

I also express my gratefulness to **Prof. Dr. Inas Elattar**, professor of Biostatistics, Department of Biostatistics & Cancer Epidemiology, National Cancer Institute, Cairo University, who kindly gave me the assistance in conducting the statistical analysis and interpretation of data.

Acknowledgements

The patients in whom I performed the study and their parents deserve my sincere gratitude.

Getting through my dissertation required more than academic support, and I would like to thank my colleagues at the department of Clinical pharmacy for their constant personal as well as professional support. I cannot begin to express my gratitude and appreciation for their friendship.

Most importantly, none of this could have happened without my husband, my children, my mother and the rest of my family members. This dissertation stands as a testament to your unconditional love and encouragement.

Table of Contents

Acknowledgements	i
Table of Contents	iii
List of Tables	vi
List of Figures.....	ix
List of Abbreviations	x
Abstract.....	xii
Introduction.....	1
Review of literature.....	4
Definitions.....	4
Incidence	4
Pathophysiology.....	5
Etiology.....	6
Genetic influences on the epilepsies	8
Classification of epileptic seizures.....	10
Generalized versus localization-related epileptic seizures	10
1-Generalized seizures	10
2- Focal Seizures.....	10
Epilepsy syndromes	12
Status Epilepticus.....	12
Seizure precipitants	13
Risk factors	14
Clinical Presentation and Diagnosis	14
Aura.....	16
Diagnosis.....	16
1-Description of events and history taking	16
2-Physical Examination	16
3-Laboratory studies	17
4-Electroencephalograph (EEG).....	17
5-Electrocardiogram (ECG).....	17
6-Neuroimaging	18
Differential diagnosis of seizures.....	18
Therapy	18

Table of Contents

Antiepileptic Drug Therapy	19
Mechanism of AEDs.....	19
Selection of AEDs.....	20
Basis for selection of AED	20
Dosing consideration	20
Complications of pharmacotherapy	24
1-Adverse Drug effects	24
2-Drug Interactions	27
The Potential of Pharmacogenetics in the Treatment of Epilepsy	30
The contribution of clinical pharmacy to the implementation and integration of pharmacogenetics in health care system	30
Genetic factors contributing to AED response	32
(1) Genes encoding drug transporters	32
(2) Genes encoding drug metabolizing enzymes	32
(3) Genes encoding AED targets	33
Valproic Acid.....	34
Mechanism of action.....	34
Clinical efficacy.....	35
Adverse Effects	35
Pharmacokinetics	37
Absorption.....	37
Distribution and Protein Binding	37
Metabolism	37
Excretion	38
Drug Interactions	39
Clinical Use and Dosing	40
Monitoring of VPA	43
Glucuronidation	44
The UDP Glucuronosyltransferase Gene Family	44
Genetic polymorphisms of UGTs	45
Aim of the work.....	47
Patients and Methods	48
[1] Patients	49
[2] Methods.....	50

Table of Contents

Results	66
Discussion.....	107
Summary and Conclusions	120
References.....	124
Appendix.....	147
الملخص العربى

List of Tables

Table 1. Causes of seizure disorders according to age groups	7
Table 2. Genes and loci for pediatric genetic epilepsies.....	9
Table 3. Types of epileptic seizures.....	11
Table 4. Status epilepticus precipitating events	13
Table 5. Seizure types and characteristics.	15
Table 6. Differential diagnosis of seizures	18
Table 7. Evidence-based guidelines for initial monotherapy treatment of epilepsy.....	23
Table 8. Effect of Antiepileptic drugs on hepatic drug metabolizing enzymes.....	28
Table 9. Drugs that affect the pharmacokinetics of VPA	41
Table 10. Interactions of VPA with an effect on the pharmacokinetics of other drugs.....	42
Table 11. Checklist for the most common treatment-related adverse drug reactions of valproic acid.....	62
Table 12. Demographic characteristics of epileptic children.....	67
Table 13. Seizures types and clinical characteristics of epileptic children.....	69
Table 14. Treatment characteristics of epileptic children	72
Table 15. Genotype frequencies of UGT1A6 541A>G and 552A>C in epileptic patients of the study as compared with different populations	75
Table 16. Genotype frequencies of both UGT1A6 541A>G and 552A>C polymorphisms in epileptic patients	76
Table 17. Allele frequency calculated from observed genotype frequency in epileptic patients.....	76
Table 18. Comparison of Age, weight and gender distribution between wild and variant genotypic groups of UGT1A6 541A>G and 552A>C polymorphisms in epileptic patients..	78
Table 19. Association of UGT1A6 541A>G and 552A>C genotypes with maximum VPA dosage, C_{ss} and CDR, in epileptic children.....	79
Table 20. Association of UGT1A6 541A>G and 552A>C genotypic groups with maximum VPA dosage, C_{ss} and CDR, in epileptic children.....	81
Table 21. Association of allelic groups of UGT1A6 541A>G and 552A>C polymorphisms with maximum VPA dosage, C_{ss} and CDR, in epileptic children	81
Table 22. Seizure characteristics at follow up for epileptic children.....	83
Table 23. Association of UGT1A6 541A>G and 552A>C genotypic groups with seizure frequency in epileptic children.....	83

List of Tables

Table 24. Association of UGT1A6 541A>G and 552A>C genotypes with seizure severity score on Chalfont scale, in epileptic patients.....	85
Table 25. Association of UGT1A6 541A>G and 552A>C genotypic groups with seizure severity score on Chalfont scale, in epileptic patients	85
Table 26. Frequency of adverse drug reactions of valproic acid experienced by epileptic children	87
Table 27. Association between genotypic groups of UGT1A6 541A>G and fatigue, difficulty in concentration and/ poor scholastic achievement and hyperactivity as ADR to VPA.....	90
Table 28. Association between genotypic groups of UGT1A6 552A>C and fatigue, difficulty in concentration and/ poor scholastic achievement and hyperactivity as ADR to VPA.....	91
Table 29. Association between genotypic groups of UGT1A6 541A>G and decreased appetite +/- poor weight gain, alopecia +/- curling and insomnia, as ADR to VPA	93
Table 30. Association between genotypic groups of UGT1A6 552A>C and decreased appetite +/- poor weight gain, alopecia +/- curling and insomnia, as ADRs to VPA.....	94
Table 31. Association between genotypic groups of UGT1A6 541A>G and drowsiness, obesity with/without increased appetite, irritability and headache, as ADRs to VPA	96
Table 32. Association between genotypic groups of UGT1A6 552A>C and drowsiness, obesity with/without increased appetite, irritability and headache, as ADRs to VPA	97
Table 33. Association between wild type and variant genotypic groups of UGT1A6 541A>G and UGT1A6 552A>C polymorphisms, and the number of ADRs per patient.....	98
Table 34. Laboratory data at baseline and follow up, for epileptic children	100
Table 35. Effect of co-medication with l-carnitine on seizure frequency in epileptic children	101
Table 36. Effect of co-medication with l-carnitine on the frequency of headache, irritability and hyperactivity as ADRs to treatment with VPA in epileptic children	101
Table 37. Effect of co-medication with l-carnitine on the frequency of drowsiness, fatigue and insomnia as ADRs to treatment with VPA in epileptic children	102
Table 38. Effect of co-medication with l-carnitine on the frequency of decreased appetite +/- poor weight gain, alopecia +/- curling and obesity +/- increased appetite as ADRs to treatment with VPA in epileptic children	103
Table 39. Effect of co-medication with l-carnitine on the frequency of difficulty in concentration and/ poor scholastic achievement as an ADR to treatment with VPA in epileptic children.....	104

List of Tables

Table 40. Correlation between serum VPA concentration and daily VPA dose, number of seizures per month (during 6 months follow up), number of ADRs per patient and Chalfont seizure severity score	106
--	-----

List of Figures

Figure 1. A timeline of antiepileptic drugs	21
Figure 2. Overview of antiepileptic drug treatment response.....	22
Figure 3. Pathways of valproic acid elimination with candidate genes involved in metabolism	39
Figure 4. Glucuronidation reaction of valproic acid.....	44
Figure 5. UGT1 gene locus consisting of four common exons, nine first exons and four pseudogenes	46
Figure 6. Schematic representation of the study design.	48
Figure 7. Chalfont Seizure Severity Scale	63
Figure 8. Distribution of different seizure types among epileptic children	70
Figure 9. Valproic acid brands used in the treatment of epileptic children.	72
Figure 10. Electrophoresis pattern of PCR fragments after digesting with <i>NsiI</i> for the UGT1A6 541A>G polymorphism.	74
Figure 11. Electrophoresis pattern of PCR fragments after digesting with <i>Fnu4HI</i> for the UGT1A6 552A>C polymorphism.	74
Figure 12. Adverse drug reactions of valproic acid experienced by epileptic children.....	88
Figure 13. The response and prognosis of epileptic children to valproic acid therapy	105

List of Abbreviations

AAN	American Academy of Neurology.
ABCB1	ATP-Binding Cassette, Sub-Family B, Member 1
ADR	Adverse Drug Reaction
AEDs	Antiepileptic Drugs
AUC	Area Under the Plasma Concentration-Time Curve
BID	bis in die, twice a day
CDR	Concentration to Dose Ratio
CT	Computerized Tomography
CYP P450	Cytochrome P450
DNTP	Deoxynucleotide Triphosphate
EDTA	Ethylenediaminetetraacetic Acid
EEG	Electroencephalography
EPC	Epilepsia Partialis Continua
FLAIR	Fluid-Attenuated Inversion Recovery
G6PDH	Glucose-6-Phosphate Dehydrogenase
GABA-A	γ -Aminobutyric Acid, Subunit A
GCSE	Generalized Convulsive Status Epilepticus
ILAE	International League Against Epilepsy
LD	Linkage Disequilibrium
MDR	Multi-Drug Resistance Gene
MRI	Magnetic Resonance Imaging
NAD	Nicotinamide Adenine Dinucleotide
NICE	The National Institute For Clinical Excellence In The United Kingdom.
PCR	Polymerase Chain Reaction
PCR-RFLP	Polymerase Chain Reaction-Restriction Fragment Length Polymorphism
PT	Prothrombin Time
PTT	Partial Thromboplastin Time
SCN1A	Sodium Channel Gene
SD	Standard Deviation
SIGN	Scottish Intercollegiate Guidelines Network.
SMA	Supplementary Motor Area
SNP	Single Nucleotide Polymorphism

List of Abbreviations

TAE	Tris-Acetate-EDTA
TIA	Transient Ischemic Attack
TID	ter in die, three times a day
TNF	Tumor Necrosis Factor
UDGPA	Uridine 5'-Diphosphate-Glucuronic Acid
UGT	Uridine Diphosphate Glucuronosyltransferase
VPA	Valproic Acid

Abstract

Background/objective: Valproic acid (VPA) is widely used in pediatric epilepsy. It is mainly eliminated through conjugation by UDP-glucuronosyltransferases which are known to be polymorphic. The aim of the study was to investigate the effect of UGT1A6 polymorphism at 541A>G and 552A>C loci on the serum level of VPA and overall clinical response. Seizure control and incidence of adverse drug reactions (ADR) were investigated in a cohort of Egyptian children with idiopathic epilepsy.

Methods: Genetic polymorphisms were detected in 48 patients receiving VPA monotherapy by PCR-RFLP. Steady state concentrations at trough level were determined by homogenous enzyme immunoassay technique. All patients were monitored for seizure frequency and seizure severity (SS) using Chalfont SS scale as well as for ADRs.

Results: Patients of variant genotype group (AC & CC) had lower concentration dose ratios (CDRs) than those with (AA) genotype for UGT1A6 552A>C ($p=0.029$). For both UGT1A6 541A>G and 552A>C, the median CDR of variant allele carriers was significantly lower than wild-type allele carriers ($p=0.047$ and $p=0.001$, respectively). Higher SS scores on Chalfont scale were associated with (AA) genotype of UGT1A6 552A>C than variant genotypes group (AC & CC) ($p=0.020$). No significant effect was detected on seizure control, while fatigue and cognitive adverse effects were significantly higher in wild genotype group of UGT1A6 552A>C and variant genotype group of UGT1A6 541 A>G, respectively.

Conclusion: UGT1A6 polymorphisms at 541A>G and 552A>C loci may be associated with increased VPA metabolism in Egyptian epileptic children. The severity of seizures as well as susceptibility to certain ADRs may be linked to the presence of certain UGT1A6 genotypic variants.

Introduction

Epilepsy is a chronic neurological condition manifesting as recurrent, unprovoked epileptic seizures. It is one of the most common chronic neurological diseases, with an estimated 50 million people affected worldwide (*Duncan et al., 2006*). Epilepsy is an extremely heterogeneous disorder, comprising a large spectrum of different seizure and syndrome types with multiple underlying etiologies (*Bhalla et al., 2011*).

Antiepileptic drugs (AED) are the primary form of treatment for seizures and epilepsy, while brain surgery and vagal nerve stimulation are reserved for selected refractory cases (*Elger and Schmidt, 2008*). Pharmacotherapy is fraught with problems mainly related to the unpredictability of efficacy, adverse drug reactions (ADRs) and optimal dosing in individual patients (*Depondt, 2008*).

The choice of drug and initial dosing is mainly based on factors such as epilepsy type, patient's age, gender, co-medication, and concomitant diseases (*Elger and Schmidt, 2008*). Further dose adjustments are based on seizure frequency and occurrence of ADRs. This may consume a considerable time of trial and error before an acceptable balance is achieved between efficacy and toxicity (*Berg and Chadwick, 2000; Loscher et al., 2009*).

AED efficacy, toxicity and dosing are influenced by multiple factors including environmental factors, patient-related factors, as well as genetic factors (*Evans and McLeod, 2003*). Identification of genetic factors influencing AED response could enable prediction of response in individual patients which is the essence of the pharmacogenetic studies. This could lead to more rapid seizure control with fewer ADRs and thus to an improved quality of life for patients with epilepsy (*Loscher et al., 2009*).

Genetic association studies are currently the most widely used approach where correlations between genetic variants and phenotypical differences are assessed on a population scale, to identify genetic variations contributing to variable drug responses (*Goldstein et al., 2003*). Increased knowledge of genetic associations with drug response is becoming more available making it possible that genetic information could be commonly used to guide drug therapy decisions in the near future (*Johnson, 2013*).

Clinical pharmacists have an established role in the health care setting, including education for both patients and providers, selecting and monitoring drug therapies for individual patients, ensuring safe and appropriate use of medications in populations, as well as conducting clinical research (*El-Ibiary et al., 2008*). Pharmacogenetic information serves

as a potential tool providing unique opportunities for clinical pharmacists to expand these roles, thereby, optimizing drug treatment for individual patients (**Brock et al., 2003**).

Valproic acid (VPA) is one of the major antiepileptic drugs with high efficacy against multiple seizure types, including both primarily generalized and partial seizure in adults and children (**Loscher, 2002**). Serious adverse effects, despite being rare, including fatal hepatotoxicity, acute pancreatitis, encephalopathy as well as bone-marrow suppression, have been associated with VPA treatment (**Gerstner et al., 2007**).

Therapy with VPA is clinically complicated by high interindividual variability in both pharmacokinetics and pharmacodynamics giving rise to a wide dosing range and therapeutic plasma level of 50-100 mg/l which necessitates its blood level monitoring during therapy (**Jiang and Wang, 2004; Ferraro and Buono, 2005**).

Glucuronidation and β -oxidation are the principal pathways of VPA metabolism, with glucuronidation reaching up to 50% of the total metabolism of the initial dose (**Ito et al., 1990; Argikar and Remmel, 2009**). Glucuronidation involves the conjugation of a glucuronic acid moiety to a range of functional groups of a specific substrate increasing their polarity which facilitates their excretion in bile or urine (**Guillemette, 2003**). It is carried out by Uridine diphosphate glucuronosyltransferase (UGTs), a superfamily of enzymes (>16) expressed on the inner membrane of the endoplasmic reticulum and are categorized into three subfamilies: UGT1A, UGT2A, and UGT2B (**Mackenzie et al., 1997**). Glucuronidation of VPA has been reported to be carried out by UGT1A3, UGT1A6, UGT1A9, UGT2B7, and UGT2B15 (**Ethell et al., 2003; Argikar and Remmel, 2009**).

UGT1A6 gene was demonstrated to be highly polymorphic with at least four alleles characterized by three single nucleotide polymorphisms (SNPs) including polymorphisms rs2070959 (541A>G) and rs1105879 (552A>C), rs6759892 (19T>G) in the coding sequence which can lead to both transcriptional and functional changes of its encoded enzymes (**Ciotti et al., 1997; Nagar et al., 2004**). Genetic polymorphisms in UGT1A6 are highly prevalent in different racial populations and the frequency of some variant alleles has shown different distribution between Caucasians and Asians (**Lampe et al., 1999**).

Studies investigating the clinical implications of these variant alleles are of great importance for clinical practice as they help assess the required dose of VPA in different populations.

Few studies are available on the effect of UGT1A6 gene polymorphisms on the levels of VPA in epileptic patients. All of them were carried out in Asian populations of different ethnic backgrounds; moreover, the results generated from these studies were not entirely